Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Fluence Corporation has added another US industrial water project to its order book, securing a contract worth about US$3.7 million to design and build a water treatment plant for a prominent manufacturer in Texas. The plant will use ultrafiltration and reverse osmosis technologies and is expected to be installed and fully operational by the end of 2026.

For investors, the dollar value is not company-transforming on its own. But the strategic signal is more interesting. Fluence is pitching itself into the intersection of industrial water security, decentralised treatment and climate-stressed US manufacturing regions. Texas, with its periodic droughts, fast-growing industrial base and pressure on municipal water systems, is a useful proving ground.

The project will treat groundwater from an on-site well for use as cooling tower makeup water. Once complete, the facility is expected to produce up to 1.5 million gallons per day, reducing the customer’s reliance on municipal water supplies. Fluence says the system is designed to achieve more than 90% recovery of feedwater, which matters because industrial customers are not just trying to access water, they are increasingly trying to squeeze more output from every litre available.

Water security becomes an operating issue

Chief executive and managing director Ben Fash framed the contract as part of a broader shift among industrial manufacturers facing water scarcity.

“Industrial manufacturers across Texas and other drought-stricken regions in the US are increasingly confronting the reality that water security could become an operational issue,” Fash said. He added that advanced water treatment could help industry maintain production while supporting broader conservation goals during periods of extreme drought.

That is the nub of the investment case Fluence is trying to sharpen. Water treatment is no longer purely a municipal infrastructure story, nor only an environmental compliance cost. For some industrial users, particularly in water-stressed regions, supply reliability is becoming a production risk. Cooling towers are not glamorous, but if they are short of water, the factory does not run as intended.

Fluence’s pitch is that its quick-to-deploy systems can meet tight quality requirements while helping customers become less dependent on public networks. That decentralised angle is important. Rather than waiting for large civic infrastructure upgrades, industrial users can install dedicated treatment capacity on site.

Industrial growth is the main prize

Fluence says the Texas contract forms part of its growing portfolio of industrial projects in the US. The company describes itself as active in wastewater treatment and reuse, high-strength wastewater treatment, wastewater-to-energy, industrial and drinking water markets, with standardised products including Aspiral, NIROBOX, SUBRE and Nitro. It also offers operations and maintenance support, Build Own Operate structures and other recurring revenue models.

That recurring revenue point is worth watching. One-off equipment contracts can be lumpy, especially for a smaller ASX-listed company. Investors will want to see whether Fluence can turn project wins into a steadier base of service, maintenance or long-term operating revenue. A US$3.7 million plant is welcome. A repeatable platform across multiple industrial customers would be more valuable.

Fash was clearly leaning into that ambition, saying Fluence hopes to provide solutions to “many other industrial customers facing similar challenges in the US and abroad”.

Market context for FLC holders

Fluence remains a small-cap stock, so contract news can loom larger than it would for a bigger industrial.

That size cuts both ways. Smaller contracts can be meaningful for revenue visibility, but execution risk is also magnified. Investors will want to track whether the plant is delivered on schedule, whether margins are attractive, and whether the project leads to follow-on work in Texas or other drought-affected US regions.

The key point is that Fluence is not merely selling a piece of water kit. It is selling operational resilience to manufacturers whose water supply assumptions are becoming less comfortable. If management can convert that theme into a broader pipeline of industrial orders, the Texas win may prove more significant than its headline contract value suggests.

Archer Materials has given investors another breadcrumb on the long road from deep-tech promise to manufacturable quantum devices, saying it remains on track to demonstrate a working qubit this year while pushing its graphene-based device work toward wafer-scale production.

For a company such as Archer, the headline is not merely that the qubit program is progressing. The more commercially important message is that management is trying to drag the technology out of the lab coat phase and into the world of repeatable semiconductor manufacturing. That is where things become more interesting for investors, because quantum technologies are only valuable at scale if they can be made reliably, consistently and, eventually, economically.

Archer says it has now completed multiple design, fabrication and testing cycles across its quantum device program. These cycles have helped refine device structures, validate critical components and build confidence that its processes could be compatible with larger-scale semiconductor manufacturing.

Why wafer-scale matters

Wafer-scale manufacturing is a dry phrase, but it is doing a lot of heavy lifting here. It means Archer is thinking about how its devices might be produced using processes closer to those already used by semiconductor foundries, rather than as one-off laboratory specimens.

The company says the move toward wafer-scale processes should support improved consistency, reproducibility across fabrication runs, higher throughput and better compatibility with industrial foundry environments.

For investors, that matters because the quantum sector is littered with technically impressive claims that struggle to make the jump into manufacturable hardware. A single qubit demonstration would be a scientific milestone. A pathway to manufacture would be the more commercially relevant bridge.

Archer chief executive Dr Simon Ruffell described the progress toward wafer-scale manufacturing as an “important technical and strategic milestone”, adding that the company is working toward technologies that can integrate into existing semiconductor supply chains.

The graphene angle

Archer’s qubit program is built around graphene and semiconductor device capabilities. Recent work has focused on characterising graphene materials and fabricated devices, with the data feeding back into future qubit designs and processing methods.

That sounds wonky, because it is. But the investment relevance is straightforward: Archer is trying to build a repeatable knowledge base around how these materials behave when turned into functional devices.

The company is also careful to point out that the same underlying capabilities may have uses beyond quantum computing. Management namechecks potential applications in terahertz sensing, photonics, artificial intelligence infrastructure, cloud technologies and other quantum-enabled systems.

That is useful optionality. It also means investors should judge Archer not only on the binary question of whether it produces a working qubit this year, but on whether its broader platform of graphene and semiconductor know-how can generate commercial pathways in adjacent markets.

The investor read-through

Archer is still a pre-commercial deep-tech story, so the usual caveats apply. Technical progress does not automatically translate into revenue, customers, margins or defensible market share. Quantum computing remains a brutally complex field, and global competition is hardly thin on the ground.

However, the update gives investors a clearer sense of the next gating item. Archer is aiming to demonstrate a working qubit, then increasingly focus on transferring fabrication processes into foundry-compatible environments and improving qubit performance.

That sequencing is important. First prove the device can work. Then prove it can be improved. Then prove it can be made in a way that fits with the semiconductor ecosystem. Only then does the bigger commercial conversation become more tangible.

Archer has a market capitalisation of about $76.45 million, placing it firmly in the speculative end of the technology market rather than the institutional heavyweight category.

A milestone year, but not the finish line

The key phrase for investors is “on track”. Archer says it remains on track to demonstrate a working qubit this year, which would be a major credibility marker for the company’s quantum technology program.

But the real prize is not a science trophy for the cabinet. It is whether Archer can turn that milestone into a manufacturable technology platform with relevance across computing, sensing and advanced semiconductor markets.

For now, Archer has strengthened the narrative that it is not merely tinkering at the edges of quantum hardware. It is trying to build devices that could, in time, be made through scalable semiconductor processes. That is still a long road, but at least the road now has a few more signposts.

Metallium has given investors a useful temperature check on its Texas scale-up story, successfully completing a 12-hour continuous campaign using its Generation-1 commercial-scale Flash Joule Heating reactor at the Gator Point Technology Campus in Chambers County. The company says the run showed stable, repeatable and controlled operation over an extended period, while validating reactor integrity, process stability, automation systems and operating procedures ahead of planned parallel reactor deployment.

For a technology company trying to shift from clever chemistry to industrial throughput, this is not just a lab-coat moment. It is one of those unglamorous but important milestones that separates a promising process from a potentially bankable operating platform.

At the time of writing, MTM has a market capitalisation of about $412.6 million. That already puts a fair wad of expectation into the share price, so the market will be looking for each commissioning step to reduce a specific risk rather than merely add another glossy photo of stainless steel.

Why one reactor is the gateway to many

Metallium’s scale-up plan is based on modular parallel reactors. In plain English, the company is not trying to build one monster machine and hope it behaves. It wants to increase throughput by running multiple FJH units at once under an integrated control framework.

That makes the 12-hour single-reactor campaign a necessary dress rehearsal. Before multiple reactors can be choreographed together, one commercial-scale reactor needs to show it can run steadily, safely and repeatedly for a decent stretch.

Managing director and chief executive Michael Walshe called the milestone “an important transition point” as Metallium moves from individual reactor commissioning toward sustained multi-reactor operations. He said extended operation gave critical validation of reactor integrity, process stability, automation systems and operating procedures, while reducing risk ahead of the objective of operating multiple FJH reactors in parallel.

Throughput hints, but not yet hard economics

The eye-catcher is Metallium’s statement that initial testing indicates a potential throughput uplift compared with original internal design assumptions. The reactor also exceeded internal intermediate commissioning targets, while giving the company better data on feed handling, solids movement and system integration.

That is encouraging, but investors should resist the urge to build a spreadsheet cathedral on the word “potential”. The key questions remain recovery rates, unit costs, downtime, energy intensity, consumables, labour intensity and how the system behaves over longer campaigns.

Metallium is targeting future 24-hour operating tests and multi-reactor campaigns, along with optimisation of pre-processing and downstream recovery systems. It also continues to target Stage-1 commercial-scale e-waste processing capacity in the fourth quarter of calendar 2026, with the company’s forward-looking material referring to a Stage-1 PCB processing target of about 8,000 tonnes per annum.

Feedstock flexibility adds optionality

Another useful detail is that the campaign confirmed the ability to process platinum and palladium-rich materials. That supports Metallium’s broader claim that FJH can handle a range of high-value waste and mineral feedstocks, rather than being locked into one tidy input stream.

The company says the platform is designed around configurable pre-processing, tuneable reactor conditions and adaptable downstream recovery pathways. If this flexibility holds at scale, it could reduce reliance on a single feedstock source and open up higher-value opportunities, including gallium and germanium-rich materials.

That optionality is attractive, but it also adds complexity. Different feedstocks mean different grades, impurities, handling characteristics and recovery pathways. The prize is a flexible metal recovery platform. The risk is a technology that has to prove itself again every time the feed changes.

A metallurgist joins the toolbox

Metallium has also appointed Rod Lawry to its Technical Advisory Team. He brings more than 45 years of metallurgical, project development, commissioning and operational experience across nickel, copper, gold, uranium, tin, tungsten and hydrometallurgical systems, with prior roles linked to names including Western Mining Corporation, Glencore, BHP, Newmont, Barrick Gold, Rio Tinto and SNC-Lavalin.

That matters because the next phase is less about invention and more about execution. Commissioning is where small practical problems can become big expensive ones: chutes block, sensors drift, seals fail, feed variability bites and elegant process flowsheets meet the rude habits of real material.

The investor read-through

The good news is that Metallium has ticked off a meaningful de-risking event on the road to parallel reactor deployment. The better news is that the run produced operating data that can feed directly into reactor refinement, automation, feed handling and plant integration.

The caveat is that this is still commissioning, not commercial proof. Investors should now watch for sustained multi-reactor operation, 24-hour campaign data, clearer throughput figures, recovery performance, operating cost guidance, feedstock coverage and downstream commercial arrangements.

Metallium’s story has a seductive theme: critical and precious metals recovered from waste, onshore in the US, using a modular process with potential scale advantages. The latest milestone makes that story more credible. The next few runs need to make it more measurable.

Little Green Pharma’s proposed acquisition of Cannatrek has moved a step closer to the finish line, with the key regulatory overhang now looking more manageable than feared.

The company says Cannatrek has reached an in-principle agreement with the Therapeutic Goods Administration over alleged historical breaches of the Therapeutic Goods Act and related regulations. The matter relates to Cannatrek’s past advertising of therapeutic goods, a sensitive area for medicinal cannabis companies given the tight controls around promotion, patient access and compliant communications.

Importantly for LGP investors, the expected civil penalty is understood to sit within the economic parameters already built into the transaction. LGP does not yet know the exact quantum of the penalty, and it has stressed that the amount is material. However, the company believes it remains within the limits covered by the contingent value share, or CV Share, mechanism.

That distinction matters. The Cannatrek deal has always carried a regulatory wrinkle, and the CV Shares appear designed to stop unknown liabilities from landing too heavily on existing LGP shareholders. While the penalty is not immaterial, the market is likely to focus on the fact that the issue appears to have been ring-fenced rather than allowed to become a deal-breaker.

The $6.5 million kicker

Just as notable is Cannatrek’s expected capital contribution at completion. LGP says Cannatrek anticipates bringing an additional estimated $6.5 million of capital into the merged group above the minimum agreed under the transaction documents.

For a medicinal cannabis business, cash is not a cosmetic detail. The sector has been littered with companies that discovered too late that cultivation capacity, regulatory compliance, working capital, distribution and overseas expansion all require hard dollars rather than PowerPoint ambition.

An extra $6.5 million would provide the combined entity with a little more breathing room as it seeks to integrate operations and press its advantage in Australia and offshore markets. LGP already has vertically integrated operations across Australia and Europe, including production assets in Denmark and Australia. The company says it supplies medicinal cannabis products into Australia and more than 12 export markets, with positions in France, Germany and the UK.

The Cannatrek acquisition, if completed, would add further scale in a domestic market where brand presence, prescribing channels, product breadth and compliance discipline all matter.

Conditions precedent appear on track

LGP says the parties do not currently anticipate any issues satisfying the remaining conditions precedent to the scheme. That is another useful signal for investors watching the transaction timeline.

Schemes of arrangement are legal and procedural beasts, and even friendly deals can stall if conditions are not met, court approvals are delayed or shareholder support wobbles. The company’s message is that the machinery is still moving.

The next key event is the LGP general meeting, scheduled for 3.30pm Perth time on 22 May 2026. Shareholders will vote on the resolution to approve the issue of new LGP ordinary shares and new LGP CV Shares connected with the Cannatrek scheme consideration.

The board has unanimously recommended shareholders vote in favour of the resolution, provided no superior proposal emerges. Each LGP director also intends to vote any shares they control in favour of the resolution on the same basis.

A virtual vote with a tight timetable

The general meeting will be held virtually via Zoom. Shareholders who want to vote live at the meeting must notify the company secretary by 3.30pm Perth time on 20 May 2026. The voting eligibility record time is 5.00pm Perth time on the same day.

Proxy votes already submitted remain valid. Shareholders who have not voted, or who want to amend their vote, can do so electronically through the share registry before the proxy cut-off.

If shareholders approve the resolution and the remaining steps proceed as expected, the second court hearing is scheduled for 25 May 2026, with the scheme expected to become effective the same day. The implementation date, when consideration securities are due to be issued, is scheduled for 1 June 2026.

Why the update matters

For investors, this is less about medicinal cannabis glamour and more about transaction risk.

The TGA matter was the obvious loose thread. A material civil penalty is never welcome, but LGP’s view that it falls within the pre-agreed CV Share framework reduces the likelihood of a nasty surprise outside the negotiated deal economics. The additional capital expected from Cannatrek also helps the optics, particularly in a sector where balance sheet durability remains a recurring investor concern.

That said, the transaction is not yet complete. The penalty amount has not been disclosed, shareholders still need to vote, and court approval remains part of the process. Integration risk will also matter once the legal formalities are done.

For now, LGP has given investors a clearer read on the big regulatory question hanging over the Cannatrek acquisition. The answer is not entirely pain-free, but it looks containable. In medicinal cannabis, where the difference between growth story and cautionary tale often comes down to compliance and cash, that is no small thing.

Swift TV Ltd has taken its enterprise in-room entertainment platform out of the work camp and aged-care corridor and into the holiday resort, securing its first hospitality agreement with Daydream Island Resort in Queensland’s Whitsundays.

The deal will see Swift TV deployed across the premium resort’s 244 rooms as a recurring subscription platform. Installation is expected to start shortly, with subscription revenue to begin as rooms are commissioned.

For a micro-cap technology play, this is not yet a numbers-driven contract. Swift has not disclosed contract value, subscription pricing, expected annual recurring revenue or installation margins. But strategically, the agreement matters because it gives Swift a glossy reference site in a sector where buying decisions are often influenced by proof, peer adoption and whether the thing actually works when a guest wants to watch Netflix before dinner.

Why investors should care about the sector shift

Swift’s core proposition is an enterprise connected TV platform for managed accommodation. Historically, that has meant sectors such as mining, oil and gas and aged care, where operators need entertainment, communication tools and centralised control across large room networks.

Hospitality is a natural extension, but not an automatic win. Hotels and resorts want guest-facing technology that improves the stay, reduces friction and ideally opens extra revenue channels. They also need operational controls: secure logins, automatic logout, messaging capability and systems that do not require staff to play IT helpdesk every time a guest cannot cast from their phone.

That is where Swift is trying to position itself. The Daydream Island agreement gives the company a visible, premium resort deployment that can be shown to hotel groups and accommodation operators. In enterprise software and hardware, especially at the smaller end of the ASX, a reference site can be worth more than a brochure. It lets management say: come and see it working.

Managing director and chief executive Brian Mangano described the agreement as “an important step” in expanding Swift TV into global hospitality, saying it demonstrated the platform’s ability to deliver “a more advanced, revenue-generating in-room experience”. He added that the site is expected to support broader deployment opportunities across hotel portfolios.

The Netflix timing is handy

The resort win also follows a useful product milestone. Swift recently secured final Netflix approval for integration within its platform after a multi-year certification process involving Google and Netflix. The company said the integration allows enterprise customers to provide direct access to personal streaming subscriptions while retaining controls such as secure access, auto logout and emergency messaging over active viewing.

That matters in hospitality because the humble hotel television has become a surprisingly contested bit of real estate. Guests increasingly expect the same streaming convenience they have at home, while operators want a managed system that protects privacy and avoids operational nuisance. A platform that can combine entertainment, resort communication and enterprise controls has a clearer pitch than a plain screen with a few apps bolted on.

Market reaction and valuation context

Swift TV remains firmly in the speculative micro-cap camp, with a market capitalisation of $11.25 million.

At that size, individual customer wins can move sentiment quickly, especially when they suggest a broader addressable market. But the market will want more than a postcard from Daydream Island. The key investor questions are how quickly rooms are commissioned, what recurring revenue per room looks like, whether installation costs are recovered attractively and whether the resort reference site converts into multi-property hotel group deals.

The investor read-through

The positive interpretation is that Swift is showing cross-sector scalability. A platform that can serve mining villages, aged care facilities and a Whitsundays resort has a broader commercial story than a niche accommodation-tech product. The recurring subscription structure is also the right model if Swift can keep adding rooms without customer acquisition costs running ahead of revenue.

The more cautious view is that this is still an early-stage hospitality beachhead, not yet proof of material scale. Investors should note the absence of financial terms and the staged nature of revenue recognition as rooms are commissioned. A 244-room resort is useful, but the investment case improves only if it becomes the first domino rather than a one-off showpiece.

For now, Swift has checked into a more glamorous vertical and given itself a credible calling card. The next test is whether management can turn the Daydream Island deployment into a pipeline of hotel portfolio wins - because in micro-cap tech, the minibar money is nice, but the chain-wide rollout is where the real bill gets interesting.